Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.
NCT ID: NCT04704531
Last Updated: 2022-12-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
141 participants
INTERVENTIONAL
2022-01-03
2022-06-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) BID in OU during 30 days.
Sodium Hyaluronate Ophthalmic 0.4% BID
Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno BID.
Group 2
Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) QID in OU during 30 days.
Sodium Hyaluronate Ophthalmic 0.4% QID
Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno QID.
Group 3
Application of one drop of Multidose Lagricel® Ofteno (Sodium Hyaluronate 0.4%) 6 times per day in OU during 30 days.
Sodium Hyaluronate Ophthalmic 0.4% Six times per day
Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno six times per day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sodium Hyaluronate Ophthalmic 0.4% BID
Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno BID.
Sodium Hyaluronate Ophthalmic 0.4% QID
Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno QID.
Sodium Hyaluronate Ophthalmic 0.4% Six times per day
Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno six times per day.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Being capable of voluntarily grant a signed informed consent.
* Being willing and able to meet the requirements of the study such as attending programmed visits, treatment plan and other study procedures.
* Women in child-bearing age must assure the continuation (start ≥ 30 days prior to informed consent signing) of a hormonal contraceptive method or intrauterine device (IUD) during the study.
* Presenting a mild to moderate dry eye disease diagnosis, defined as:
* OSDI score between 13 and 32, plus one of the following:
* More than 5 dots of corneal staining
* More than 9 dots of conjunctival staining
* BUT \< 10 seconds
Exclusion Criteria
* Having participated in clinical trials within 30 days prior to signing this study's informed consent form.
* Having participated previously in this study.
* BCVA equal or worse than 20/200, in either eye.
* Diagnosis of any of the following:
* Allergic, viral or bacterial conjunctivitis
* Anterior blepharitis
* Parasite infestation of ocular structures (Demodex, for example)
* Unresolved history of ocular trauma
* Scarring diseases of the ocular surface
* Corneal or conjunctival ulcers
* Filamentary keratitis
* Neurotrophic keratitis
* Bullous keratopathy
* Neoplastic diseases of the ocular surface or ocular annexes
* Diseases presenting fibrovascular proliferations on the corneal or conjunctival surface.
* Any retinal or posterior segment diseases that require treatment or threat the visual outcome.
* Glaucoma
* Requiring management for dry eye that includes implementation of treatments described in the step 2 management recommendations of the Tear Film \& Ocular Surface Society's Dry Eye Work Shop II (TFO DEWS II).
* Previous history of drug addiction within the last 2 years prior to signing this study's informed consent form.
* Having a previous history of any ophthalmological surgical procedure, within the last 3 months prior to the informed consent signing date.
* Being a contact lens user, rigid or soft. Inclusion is possible if the use of contact lenses is suspended both during the study period and at least 15 days prior inclusion takes place.
* Previous history of any medical affliction, acute or chronic, that according to the investigator may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results.
* Known hypersensitivity to any of the components of the products used in this study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratorios Sophia S.A de C.V.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Jalisciense del Metabolismo, S.C.
Guadalajara, Jalisco, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SOPH037-1219/II
Identifier Type: -
Identifier Source: org_study_id